Abramson Cancer Center Support Grant

艾布拉姆森癌症中心支持补助金

• 批准号: 8710658
• 负责人: CHI V. DANG
• 金额: $ 1.25万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-15 至 2015-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8710658
• 关键词: Area; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Clinical; Collaborations; Community Outreach; Comprehensive Cancer Center; Cutaneous Melanoma; Detection; Development; Direct Costs; Education; Faculty; Fostering; Funding; Future; Growth; Hematologic Neoplasms; Image; Immunobiology; Interdisciplinary Study; Laboratories; Leadership; Malignant Neoplasms; Medicine; Methods; Mission; National Cancer Institute; Patient Care; Patients; Pediatric Oncology; Peer Review; Pennsylvania; Pilot Projects; Process; Radiobiology; Research; Research Activity; Research Training; Resource Allocation; Resource Sharing; Schools; Strategic Planning; Therapeutic; Translating; Translational Research; Translations; Tumor Biology; United States National Institutes of Health; Universities; anticancer research; cancer prevention; clinical practice; environmental carcinogenesis; innovation; malignant breast neoplasm; member; population based; programs; proton therapy; tobacco carcinogenesis; tumor; virology

DESCRIPTION (provided by applicant): The Abramson Cancer Center (ACC) of the University of Pennsylvania was founded in 1973 and was one of the first Comprehensive Cancer Centers designated by the National Cancer Institute (NCI). Since its inception, the ACC has been continuously funded through the NCI CCSG. The ACC is a matrix center that facilitates transdisciplinary cancer research, education, and patient care. Its 318 members are drawn from 37 Departments and 8 Schools of the University and have $168,806,933 in research and training funding (annual direct costs), a 40% increase since 2004. Of these funds, $156,713,965 is peer-reviewed and $51,462,763 is NCI funded, this funding includes 16 NIH P01s, 5 P50s, 3 P30s, and 1 P20. Commensurate with the growth in funding, the ACC has more than doubled its assigned space since 2004 with the opening of the Perelman Center for Advanced Medicine, the Roberts Proton Therapy Facility, and the Fisher and Colket Translational Research Buildings. Through the development of integrated programs of laboratory, clinical, and population-based research, the ACC seeks to foster pioneering scientific discoveries that can be translated into new methods for cancer prevention, detection, and treatment. Currently, there are 11 multidisciplinary research programs in the ACC: Immunobiology, Tumor Biology, Tumor Virology, Cancer Therapeutics, Pediatric Oncology, Radiobiology and Imaging, Melanoma and Cutaneous Malignancies, Hematologic Malignancies, Breast Cancer, Tobacco and Environmental Carcinogenesis, and Cancer Control. The Cancer Center supports 13 Shared Resources, of which 2 are new and 2 have been restructured. The continuous development of strong Research Programs and leading-edge Shared Resources, the recruitment of outstanding faculty, and the acquisition of additional research space allow the ACC to support the research activities of its members. An ongoing strategic planning/implementation process allows the ACC to identify emerging cancer research areas for future development, while guiding current activities and resource allocations. The ACC supports a wide range of seminars and retreats and promotes interdisciplinary use of research space to facilitate interaction and collaboration among its members. Developmental funds remain critical for the support of faculty recruitment and the funding of innovative pilot projects with the potential for peer-reviewed funding and translation. The ACC has an engaged leadership focused on supporting the transdisciplinary cancer research of its productive membership.

描述（由申请人提供）：宾夕法尼亚大学艾布拉姆森癌症中心（ACC）成立于1973年，是美国国家癌症研究所（NCI）指定的首批综合癌症中心之一。自成立以来，ACC一直通过NCI CCSG获得持续资助。ACC是一个矩阵中心，促进跨学科的癌症研究，教育和病人护理。其318名成员来自37个部门和8所学校的大学，并有$168，806，933的研究和培训资金（年度直接成本），自2004年以来增加了40%。在这些资金中，156，713，965美元是同行评审的，51，462，763美元是NCI资助的，这笔资金包括16个NIH P01，5个P50，3个P30和1个P20。随着资金的增长，自2004年以来，随着佩雷尔曼先进医学中心、罗伯茨质子治疗设施以及费舍尔和科尔凯特转化研究大楼的开放，ACC的分配空间增加了一倍多。通过实验室，临床和基于人口的研究的综合计划的发展，ACC旨在促进开拓性的科学发现，可以转化为癌症预防，检测和治疗的新方法。目前，ACC有11个多学科研究项目：免疫生物学，肿瘤生物学，肿瘤病毒学，癌症治疗学，儿科肿瘤学，放射生物学和成像，黑色素瘤和皮肤恶性肿瘤，血液恶性肿瘤，乳腺癌，烟草和环境致癌作用，以及癌症控制。癌症中心支持13个共享资源，其中2个是新的，2个已经重组。强大的研究计划和领先的共享资源的不断发展，优秀教师的招聘，以及额外的研究空间的收购允许ACC支持其成员的研究活动。一个持续的战略规划/实施过程，使ACC确定新兴的癌症研究领域，为未来的发展，同时指导目前的活动和资源分配。行政协调会支持各种研讨会和务虚会，并促进跨学科利用研究空间，以促进其成员之间的互动与合作。发展基金对于支持教师招聘和资助具有同行评审资金和翻译潜力的创新试点项目仍然至关重要。ACC有一个积极参与的领导层，专注于支持其富有成效的成员的跨学科癌症研究。